Can-Fite seeks licensing deals for Phase III assets at BIO 2026
Can-Fite BioPharma Ltd. will attend the BIO International Convention 2026 in San Diego to present its late-stage clinical pipeline and seek licensing partnerships. The company's focus includes Namodenoson for liver cancer and Piclidenoson for psoriasis, both in Phase III trials. Existing agreements have yielded $20 million in payments, and the company aims to secure further collaborations to enhance its global market presence.
*this image is generated using AI for illustrative purposes only.
Can-Fite BioPharma Ltd. is set to present its late-stage clinical pipeline and pursue licensing opportunities at the BIO International Convention 2026 in San Diego. The company will conduct partnering meetings from June 22 to June 25, 2026, to discuss commercialization strategies for its proprietary small-molecule drugs targeting oncological and inflammatory diseases. This engagement is critical for maximizing the global value of its clinical-stage assets through strategic partnerships.
The company's lead drug candidate, Namodenoson, is currently in a pivotal Phase III study for advanced hepatocellular carcinoma (HCC). Additionally, it is being evaluated in pancreatic cancer following a successful Phase IIa study and is undergoing a Phase IIb study for MASH. Can-Fite's other primary candidate, Piclidenoson, is in a pivotal Phase III study for psoriasis and is preparing for a Phase II study in Lowe Syndrome, a rare genetic disease.
Can-Fite's proprietary A3 adenosine receptor (A3AR) platform technology underpins its pipeline of orally administered therapies. The platform has demonstrated a favorable safety profile across more than 1,600 patients treated to date. The company has already established multiple regional licensing agreements, which have generated approximately $20 million in upfront and milestone payments, with potential for additional royalties.
Dr. Sari Fishman, Vice President of Business Development at Can-Fite BioPharma, emphasized the importance of the event for securing collaborations. "BIO International Convention is one of the most important partnering events in the biotechnology industry," said Dr. Fishman. "With two pivotal Phase III programs, an ongoing Phase IIb study in MASH, and additional opportunities in oncology and rare diseases, we look forward to meeting with potential partners to discuss licensing, commercialization, and value-creating collaborations."
Clinical Pipeline Overview
The following table summarizes the current status of Can-Fite's key drug candidates:
| Drug Candidate | Indication | Study Phase |
|---|---|---|
| Namodenoson | Advanced Hepatocellular Carcinoma (HCC) | Phase III |
| Namodenoson | Pancreatic Cancer | Phase IIb |
| Namodenoson | MASH | Phase IIb |
| Piclidenoson | Psoriasis | Phase III |
| Piclidenoson | Lowe Syndrome | Phase II |
Dr. Fishman will be available for partnering meetings throughout the conference to facilitate discussions regarding these assets.
What specific criteria will Can-Fite use to evaluate potential partners for the commercialization of Namodenoson and Piclidenoson?
How might the outcome of the ongoing Phase IIb MASH study influence the valuation of Namodenoson ahead of the BIO International Convention?
What are the anticipated timelines for the release of topline data from the pivotal Phase III studies for HCC and psoriasis?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
